Prenetics Global Ltd

Prenetics Global Limited announced a $1 billion growth financing agreement with General Catalyst's Customer Value Fund for its AI-native wellness brand, IM8. This non-dilutive financing will fund up to 70% of IM8's marketing spend, with General Catalyst receiving a capped share of income tied to customer cohort performance. The company also raised IM8's full-year 2026 revenue guidance to $210–220 million and expects IM8 to reach $400 million or more in full-year 2027 revenue, accelerating its growth strategy.

Prenetics Global Limited announced that its AI-native wellness brand, IM8, has secured $1 billion in growth financing from General Catalyst's Customer Value Fund. This non-dilutive arrangement will fund up to 70% of IM8's marketing spend, allowing for accelerated growth without issuing equity. Following this, Prenetics raised its full-year 2026 IM8 revenue guidance to $210-$220 million and projects IM8 to reach $400 million or more in full-year 2027 revenue.

Prenetics Global Ltd reported strong Q1 2026 financial results, driven by its IM8 brand, with total revenue of $36.0 million and IM8 revenue reaching $33.8 million, a nearly 6x increase year-over-year. The company raised its full-year 2026 IM8 revenue guidance to $190 million-$210 million and projected Q2 2026 revenue between $46 million and $48 million. Prenetics also announced the full divestment of its digital asset holdings for $41.3 million and the appointment of Brian J. Rosin as the new CFO for IM8. Despite a reported loss from operations, the company highlighted significant growth in IM8's annualized recurring revenue, which reached approximately $200 million in May 2026.

Prenetics Global Ltd reported strong Q1 2026 results, with total revenue reaching $36.0 million, a significant increase driven by its IM8 brand which generated $33.8 million in revenue, up nearly 6x year-over-year. The company raised its full-year 2026 IM8 revenue guidance to $190 million-$210 million and projects Q2 2026 revenue between $46 million and $48 million. Prenetics also divested its digital asset holdings for $41.3 million and appointed Brian J. Rosin as the new CFO of IM8.

Prenetics Global Ltd announced the appointment of Hudson Leogrande, Founder and CEO of the multi-billion-dollar DTC brand Comfrt, to its Board of Directors as an independent director. This strategic move aims to leverage Mr. Leogrande's expertise in social commerce to accelerate the expansion of Prenetics' premium health and longevity brand, IM8, across TikTok Shop and Meta. IM8 has demonstrated rapid growth, reaching $100 million in annualized recurring revenue in 11 months and is projected to hit $250 million to $300 million ARR by the end of 2026, with Prenetics raising its full-year 2026 IM8 revenue guidance to $190 million to $210 million. The appointment also enhances corporate governance, with three of four directors now being independent.

Prenetics Global Limited announced the appointment of Hudson Leogrande, Founder and CEO of Comfrt, to its Board of Directors as an independent director. This appointment enhances the company's corporate governance, with three of its four directors now independent, and brings significant expertise in scaling direct-to-consumer brands through social commerce. IM8, Prenetics' premium health brand, has achieved rapid growth, surpassing $100 million in annualized recurring revenue in 11 months and is projected to reach $250 million to $300 million ARR by the end of 2026, with full-year 2026 revenue guidance raised to $190 million to $210 million.

Prenetics Global Limited announced a multi-year global partnership with Jay Shetty, who will serve as IM8's Global Ambassador and become a shareholder in Prenetics. This partnership extends IM8's reach beyond sports into wellness and mindfulness. Following nearly 6x year-over-year growth in Q1 2026, IM8 also raised its full-year 2026 revenue guidance to $190 million to $210 million.

Prenetics Global Ltd announced preliminary Q1 2026 results, reporting $36.0 million in revenue, a 334.5% increase year-over-year. Its IM8 brand revenue reached $33.8 million, growing nearly 6x year-over-year and 23.1% sequentially. The company raised its full-year 2026 IM8 revenue guidance to $190 million-$210 million and projects Q2 2026 revenue of $46 million-$48 million. Additionally, Prenetics divested its digital assets for $41.3 million and executed $19 million of its $40 million share buyback program.

Prenetics Global Ltd, parent company of the premium health and longevity brand IM8, announced the appointment of Brian J. Rosin as U.S. Chief Financial Officer. Mr. Rosin will lead the finance organization, reporting to CEO Danny Yeung, and will establish dedicated finance leadership for IM8 to support its rapid global expansion. IM8, co-founded with David Beckham, is projecting $190 million to $210 million in revenue for 2026, its second year from launch, and has already surpassed $100 million in annualized recurring revenue within 11 months. Rosin brings nearly two decades of financial leadership in consumer e-Commerce and premium wellness brands.

Prenetics Global Limited announced it will release its first quarter 2026 financial results before market open on Thursday, May 14, 2026. The company will also host an earnings conference call on the same day at 10:00 a.m. Eastern Time to discuss the results in detail, concluding with a Q&A session for analysts. Dial-in and webcast information were provided for interested parties.